Needham, Absci
"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...
Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in ...
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...
Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...
We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.14, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 2.06% ...
Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that ...
Advanced Micro Devices is investing $20 million in Absci, a drug-discovery company based in Washington state, in a move aimed at selling its artificial intelligence chips in the healthcare sector.
Absci management is scheduled to participate in a fireside chat on Wednesday, February 5 th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback